TriNetX, LLC

None\n Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial protocols, enhancing recruitment, and accelerating timelines.AI and RWD Synergy: The TriNetX Impact One notable application of AI and RWD is the digital waiting room, an innovative approach that allows physicians to monitor potential trial candidates in real time before they meet eligibility criteria. TriNetX leverages extensive electronic health record (EHR) datasets to identify these candidates, ensuring a steady pipeline of eligible participants and improving overall recruitment efficiency. AI and RWD are also instrumental in advancing diversity in clinical trials. Recognizing the challenges of meeting diversity enrollment targets, TriNetX collaborated with a pharmaceutical company to develop a machine learning (ML)-based diversity protocol evaluation model. This model optimizes trial protocols by analyzing different combinations of eligibility criteria, ensuring a balance between diversity and scientific integrity. Beyond recruitment and diversity, AI-driven models are reshaping disease prediction and intervention strategies. One such breakthrough involves predicting inflammatory bowel disease (IBD) progression and flares. In collaboration with a pharmaceutical company, TriNetX developed an ML model that uses real-time clinical data to identify IBD patients at risk of treatment escalation within seven days, enabling clinical trial coordinators to prioritize patients with the highest risk. This innovative approach has the potential to significantly improve trial enrollment success rates, increasing clinical trial conversion from 33 percent to as high as 85 percent for Crohn’s disease and 70 percent for ulcerative colitis. A breakthrough in early pancreatic cancer detection is emerging through ML as well. Traditional screening guidelines primarily focus on genetic or familial risk factors, which account for only 10 percent of pancreatic cancer cases. To expand detection beyond these limited criteria, the ML model analyzed a vast dataset of 35,000 pancreatic cancer patients and 1.5 million non-cancer patients across 55 health systems. This analysis identified 87 top predictive features for Pancreatic Ductal Adenocarcinoma (PDAC), offering a more comprehensive approach to assessing risk. What makes this model particularly powerful is its ability to predict who is at risk of developing pancreatic cancer within the next 18 months. By generating risk thresholds with varying performance metrics, the model allows for tailored decision-making. Depending on the chosen threshold, physicians can take different courses of action—ranging from sending high-risk patients directly to imaging to using the model as a standalone early detection tool. Alternatively, a broader threshold could be set, casting a wider net for potential cases, followed by biomarker testing to refine the at-risk population. For instance, CA 19-9, a well-established biomarker for pancreatic cancer, could be integrated into a tiered screening approach. The model would first identify an enriched at-risk population from the general public, which would then undergo biomarker testing before proceeding to imaging. To validate this approach, a pilot study is currently underway at one healthcare organization, where researchers are acting on the model’s predictions by recruiting patients above a certain risk threshold for biospecimen collection and biomarker analysis.  Additional AI and RWD BreakthroughsAI and RWD are making an impact in several other areas of healthcare innovation. Here are three more applications:Unveiling Disease Progression Patterns: AI-powered predictive analytics enable researchers to tailor trials to patient subgroups most likely to respond positively to treatment. This data-driven precision minimizes trial-and-error approaches, significantly enhancing efficiency.Ushering In an Era of Personalized Medicine: AI is paving the way for precision medicine, where treatments are tailored to individual patients based on genetic, biological, and lifestyle factors. For example, AI-powered tools are already being used to predict which prostate cancer patients will benefit from additional hormonal therapy when undergoing radiation treatment.Repurposing Existing Drugs with AI Insights: By analyzing vast datasets, AI identifies hidden correlations between existing drugs and new therapeutic applications. This accelerates drug discovery while reducing costs by repurposing already-approved compounds.The Future of Clinical Research The convergence of AI and RWD is driving one of the most profound transformations in modern medicine. However, as AI reshapes healthcare, ethical considerations—such as data integrity, algorithmic bias, and transparency—must remain at the forefront. Continuous validation of AI models is essential to ensure accuracy and fairness across diverse patient populations. By utilizing large, representative datasets and embedding ethical AI practices, researchers can develop models that are not only powerful but also responsible. The future is now. AI-driven insights are helping to expedite drug approvals, deliver more effective treatments, and ultimately improve patient outcomes worldwide. The question is no longer whether AI will revolutionize clinical research but how quickly we can implement these breakthroughs to maximize their impact on global health.Want to revolutionize your clinical trials and speed up drug development? Discover how TriNetX AI and RWD can make it happen. 

Kauvery Hospital invests in Lifesigns Lifesigns has received undisclosed funding from Kauvery Hospital Group's investment arm, Healthcare Capital. The new funds, based on a press statement, will "advance Lifesigns’ AI and predictive algorithm capabilities." The company offers an AI-powered remote patient monitoring system that provides alerts and predictive insights. Lifesigns is now gearing for its next fundraising, where it plans to launch a new product and introduce expansion initiatives. AI-powered sleep apnoea app now prescribed at major Korean hospital Seoul National University Bundang Hospital is the first among hospitals in South Korea to prescribe an AI-powered mobile application for diagnosing sleep apnoea. The diagnostic support tool called Apnotrack by medical AI company Asleep records a user's breathing and then uses AI to assess for sleep apnoea. Asleep claims its app to have comparable performance with at-home polysomnography tests. Apnotrack received an innovative medical device designation from the South Korean government in 2023 and was approved as a Class II medical device by the Ministry of Food and Drug Safety last year. TriNetX launches JV with Fujitsu in Japan Global health research network TriNetX has partnered with Fujitsu to launch a joint venture in Japan. The JV, according to a press release, will provide healthcare researchers and pharmaceutical companies in Japan with secure access to big medical and health datasets. TriNetX runs a self-service data exploration platform for clinical researchers, featuring over 200 million patient records. Its integration with Fujitsu's cloud-based healthcare platform will "create an environment where Japanese medical data, previously underutilised, can be efficiently leveraged for clinical research," said Tatsuki Araki, head of Fujitsu's Healthy Living division.

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX's Board CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ -- TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company's Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX's Board of Directors and will be an Advisor to Carlyle, TriNetX's majority investor. Continue Reading "It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX's employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX's continued success," said Lachman. "Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas." "It has been an honor to build TriNetX and be part of such an outstanding team," said Lachman. Post this During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted. Margolis said, "I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world's top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership." Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX's lead investor, added, "We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success." Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi's exceptional legacy. About TriNetX, LLC TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at or follow TriNetX on LinkedIn. Media Contact TriNetX Michelle Fleming, Chief Marketing Officer Email: [email protected] SOURCE TriNetX WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED